Pharmaceutical-biotechnology interface, formulations design containing active metabolites from LAB

CABRERA CARLA AGOSTINA; ALBERTO N RAMOS; SESTO CABRAL, MARÍA EUGENIA; MARIA DE LOS ANGELES LINDON; MARIA EMILIA CRUZ; JUAN C VALDEZ

Tucuman

Simposio; IV Simposio Internacional de Bacterias Lácticas SIBAL; 2013

CERELA

Chronic wounds are those that are arrested in the inflammatory stage of healing. Regardless of the background pathology, the main cause of chronicity is infectionproduced by biofilm forming bacteria. These can adhere to a living tissue and grow embedded in a matrix of polymers producing by themselves.This confers them resistance to antibiotics, antiseptics and immune system. Therefore, current therapies for the treatment of these wounds require antipathogenic and pro-healing properties.Some authors ensure that Pseudomonas aeruginosa causes chronicity and perhaps represent a predisposing factor for additional bacteria colonization.In previous works we demonstrate that Lactobacillus plantarumculture supernatants of (LpS) have antipathogenic activity against P. aeruginosa inhibiting in vitro adhesion, growth, quorum sensing system, biofilm and virulence factors.Also Lps showed a significant pro-healing capacity in human chronic wounds (diabetic foot ulcers, burns, etc.).However, its liquid state makes difficult the application and therefore it reduced its therapeutic effectiveness. The aim of this work was to contribute to the development of pharmaceutical biotechnology, by designing a low-cost effective, stable and secure medicament using Lps as active pharmaceutical ingredient (API) for chronic wounds topical treatment.Semisolid formulations were designed. Besides pharmacotechnical quality controls (established by Pharmacopoeia) and in vitro release studies of API were carried out. To confirm the conservation of previously reported activities, conventional microbiological assays were adapted to evaluate the selected semisolid formulations:1) growth inhibition (growth curves in microplates), 2) biofilm formation inhibition and preformed biofilm disruption (crystal violet technique in microplates). The selected formulations showed optimum mechanical and rheological properties and a pH within the accepted range. The pharmacotechnical and antipathogenic properties were maintained for at least six months.From in vitro release studies, it was found that the active pharmaceutical ingredients were released from the formulations in optimal quantities to maintain its activities.These studies allowed also determine the repetition time of treatment and posology. This vehicle provides occlusive properties to keep moisture in wounds and promote the development of granulation tissueas required in ischemic wounds such as diabetic foot ulcers. The larger-scale production will allow the application of an adjuvant treatment for infected chronic wounds patients in hospitals of San Miguel de Tucumán, increasing the effectiveness of conventional treatments.